Clinical trial
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine…
NCT00353366 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00353366 |
|---|---|
| Title | To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination |
| Official title | Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Infections, Rotavirus, Rotavirus Vaccines |
| Intervention type | Biological, Other |
| Interventions | Rotarix, Data collection |
| Enrollment | 1,439 |
| Start date | Nov 16, 2006 |
| Primary completion | Mar 31, 2010 |
| Completion | Jul 17, 2010 |
| First posted | Jul 18, 2006 |
| Last update posted | Mar 16, 2021 |
| Countries | Philippines |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: